

# Jennifer C Nelson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12045119/publications.pdf>

Version: 2024-02-01

43  
papers

3,212  
citations

236612

25  
h-index

253896

43  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3584  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence of bias in estimates of influenza vaccine effectiveness in seniors. <i>International Journal of Epidemiology</i> , 2006, 35, 337-344.	0.9	427
2	The test-negative design for estimating influenza vaccine effectiveness. <i>Vaccine</i> , 2013, 31, 2165-2168.	1.7	406
3	The reporting of pre-existing maternal medical conditions and complications of pregnancy on birth certificates and in hospital discharge data. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 125-134.	0.7	310
4	Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. <i>International Journal of Epidemiology</i> , 2006, 35, 345-352.	0.9	247
5	Accuracy of reporting maternal in-hospital diagnoses and intrapartum procedures in Washington State linked birth records. <i>Paediatric and Perinatal Epidemiology</i> , 2005, 19, 460-471.	0.8	183
6	Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. <i>Lancet</i> , The, 2008, 372, 398-405.	6.3	159
7	Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults: A Population-Based Case-Control Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1899-1907.	1.3	155
8	Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. <i>Vaccine</i> , 2008, 26, 4947-4954.	1.7	144
9	A Population-Based Cohort Study of Undervaccination in 8 Managed Care Organizations Across the United States. <i>JAMA Pediatrics</i> , 2013, 167, 274.	3.3	140
10	When should case-only designs be used for safety monitoring of medical products?. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 50-61.	0.9	123
11	Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 792-802.	0.9	67
12	Statin use and risk of community acquired pneumonia in older people: population based case-control study. <i>BMJ: British Medical Journal</i> , 2009, 338, b2137-b2137.	2.4	66
13	Risk Factors for Community-Acquired Pneumonia in Immunocompetent Seniors. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 882-888.	1.3	66
14	Natural Language Processing to identify pneumonia from radiology reports. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 834-841.	0.9	60
15	Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 62-71.	0.9	49
16	Induction of Labor in the Absence of Standard Medical Indications. <i>Medical Care</i> , 2007, 45, 505-512.	1.1	47
17	Timely Versus Delayed Early Childhood Vaccination and Seizures. <i>Pediatrics</i> , 2014, 133, e1492-e1499.	1.0	45
18	Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 72-81.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. <i>American Journal of Epidemiology</i> , 2013, 177, 131-141.	1.6	39
20	Challenges and Opportunities for Using Big Health Care Data to Advance Medical Science and Public Health. <i>American Journal of Epidemiology</i> , 2019, 188, 851-861.	1.6	39
21	Safety of Measles-Containing Vaccines in 1-Year-Old Children. <i>Pediatrics</i> , 2015, 135, e321-e329.	1.0	38
22	Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic. <i>American Journal of Epidemiology</i> , 2013, 178, 1327-1336.	1.6	37
23	Multiply Robust Causal Inference with Double-Negative Control Adjustment for Categorical Unmeasured Confounding. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2020, 82, 521-540.	1.1	37
24	Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. <i>Vaccine</i> , 2014, 32, 3019-3024.	1.7	36
25	A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 282-290.	0.9	34
26	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. <i>Pediatrics</i> , 2019, 144, .	1.0	30
27	Injection Site and Risk of Medically Attended Local Reactions to Acellular Pertussis Vaccine. <i>Pediatrics</i> , 2011, 127, e581-e587.	1.0	24
28	Identifying optimal risk windows for self-controlled case series studies of vaccine safety. <i>Statistics in Medicine</i> , 2011, 30, 742-752.	0.8	23
29	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 973-981.	0.9	22
30	Vaccination Site and Risk of Local Reactions in Children 1 Through 6 Years of Age. <i>Pediatrics</i> , 2013, 131, 283-289.	1.0	21
31	Methods for observational post-licensure medical product safety surveillance. <i>Statistical Methods in Medical Research</i> , 2015, 24, 177-193.	0.7	15
32	Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1173-1182.	0.9	13
33	To Rule Out Confounding, Observational Studies of Influenza Vaccine Need to Include Analyses During the "Preinfluenza Period". <i>Archives of Internal Medicine</i> , 2007, 167, 1553.	4.3	12
34	Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors?. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 858-865.	0.9	10
35	Group sequential method for observational data by using generalized estimating equations: application to Vaccine Safety Datalink. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015, 64, 319-338.	0.5	9
36	A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data. <i>EGEMS (Washington, DC)</i> , 2017, 4, 17.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 707-712.	0.9	7
38	Integrating database knowledge and epidemiological design to improve the implementation of data mining methods that evaluate vaccine safety in large healthcare databases. <i>Statistical Analysis and Data Mining</i> , 2014, 7, 337-351.	1.4	5
39	A Propensity Score-Enhanced Sequential Analytic Method for Comparative Drug Safety Surveillance. <i>Statistics in Biosciences</i> , 2011, 3, 45-62.	0.6	4
40	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1223-1225.	0.9	4
41	Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring. <i>Statistics in Medicine</i> , 2015, 34, 1117-1133.	0.8	4
42	Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 77-86.	2.4	3
43	Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: Part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 114-122.	2.4	1